Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Blood|August 21, 2004
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemiaMichele Baccarani, Giovanni Martinelli, Gianantonio Rosti, et al.
Cancer|March 3, 2018
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinibFabio Efficace, Fausto Castagnetti, Bruno Martino, et al.
Haematologica|July 30, 2016
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patientsFausto Castagnetti, Massimo Breccia, Gabriele Gugliotta, et al.
Haematologica|June 27, 2015
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemiaGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Haematologica|April 7, 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 studyGabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2016
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysisMassimo Breccia, Guendalina Graffigna, Sara Galimberti, et al.
American Journal of Hematology|October 23, 2016
A population-based study of chronic myeloid leukemia patients treated with imatinib in first lineFausto Castagnetti, Francesco Di Raimondo, Antonio De Vivo, et al.
American Journal of Hematology|October 15, 2013
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib eraMichele Malagola, Massimo Breccia, Cristina Skert, et al.
Hematological Oncology|May 9, 2025
Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient PopulationMassimo Breccia, Antonella Russo Rossi, Valentina Giai, et al.
Blood Advances|December 24, 2019
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WPMichele Baccarani, Elisabetta Abruzzese, Vincenzo Accurso, et al.
Pageof 2